Zobrazeno 1 - 10
of 76
pro vyhledávání: '"David L Shelton"'
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0125127 (2015)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a soluble protein that directs membrane-bound receptors to lysosomes for degradation. In the most studied example of this, PCSK9 binding leads to the degradation of low density lipoprotein rece
Externí odkaz:
https://doaj.org/article/79a083469b90460f86e17114043f2cee
Autor:
Magdalena Dorywalska, Pavel Strop, Jody A Melton-Witt, Adela Hasa-Moreno, Santiago E Farias, Meritxell Galindo Casas, Kathy Delaria, Victor Lui, Kris Poulsen, Janette Sutton, Gary Bolton, Dahui Zhou, Ludivine Moine, Russell Dushin, Thomas-Toan Tran, Shu-Hui Liu, Mathias Rickert, Davide Foletti, David L Shelton, Jaume Pons, Arvind Rajpal
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0132282 (2015)
The efficacy of an antibody-drug conjugate (ADC) is dependent on the properties of its linker-payload which must remain stable while in systemic circulation but undergo efficient processing upon internalization into target cells. Here, we examine the
Externí odkaz:
https://doaj.org/article/523b58d2569a488d9bf12b8cb87145b2
Autor:
Pavel Strop, Arvind Rajpal, David L. Shelton, Jaume Pons, Christopher J. O'Donnell, Davide Foletti, Shu-Hui Liu, Kathy Delaria, Thomas-Toan Tran, Meritxell Galindo Casas, Adela Hasa-Moreno, Victor Lui, Thayalan Navaratnam, Dahui Zhou, Santiago E. Farias, Ludivine Moine, Russell Dushin, Magdalena Dorywalska
Experimental Procedures for the Preparation of Linker-Payloads.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a221c603c7097472189eaf46ce305d
https://doi.org/10.1158/1535-7163.22508245.v1
https://doi.org/10.1158/1535-7163.22508245.v1
Autor:
Pavel Strop, Arvind Rajpal, David L. Shelton, Jaume Pons, Christopher J. O'Donnell, Davide Foletti, Shu-Hui Liu, Kathy Delaria, Thomas-Toan Tran, Meritxell Galindo Casas, Adela Hasa-Moreno, Victor Lui, Thayalan Navaratnam, Dahui Zhou, Santiago E. Farias, Ludivine Moine, Russell Dushin, Magdalena Dorywalska
S1. Enrichment of VC-PABC hydrolysis activity by mouse serum fractionation. S2. Testing of mouse serum enzymes for the VC-PABC linker hydrolysis activity. S3. Testing of mouse serum enzymes for cleavage activity towards the non-cleavable amino-PEG6-C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b07f5767e7793d3073dc403b33870b7e
https://doi.org/10.1158/1535-7163.22508248
https://doi.org/10.1158/1535-7163.22508248
Autor:
Susan Hurst, Cedo M. Bagi, Mark Zorbas, William J. Reagan, Mark G. Evans, Kathryn E. Gropp, Cathy S. Carlson, David L. Shelton
Publikováno v:
Toxicologic Pathology. 46:408-420
Tanezumab, an anti-nerve growth factor (NGF) antibody, is in development for management of chronic pain. During clinical trials of anti-NGF antibodies, some patients reported unexpected adverse events requiring total joint replacements, resulting in
Autor:
Gretchen Jimenez, Rolla Yafawi, Shu-Hui Liu, David L. Shelton, Zhengming Yan, Wenlian Wang, Thomas-Toan Tran, Max Hallin, Tod Smeal, Sherman Michael Chin, Kevin Lindquist, Flavia Pernasetti, Mary E. Spilker, Justine L. Lam, Cathy Zhang, Nanni Huser, Eileen R. Blasi, Colleen Brown, Marco Costa, Brett H. Simmons, Bernadette Pascual, Yin Gu, Valeria Fantin, Jyothirmayee Kudaravalli, Wei-Hsien Ho, Conglin Fan, Ishita Barman, Jing-Tyan Ma
Publikováno v:
Blood Advances. 1:1088-1100
The chemokine receptor CXCR4 is highly expressed and associated with poor prognosis in multiple malignancies. Upon engagement by its ligand, CXCL12, CXCR4 triggers intracellular signaling pathways that control trafficking of cells to tissues where th
Autor:
Pavel Strop, Russell Dushin, Janette Sutton, Guoyun Zhu, Davide Foletti, David L. Shelton, Shu-Hui Liu, Charles Holz, Arvind Rajpal, Hong Liang, Jaume Pons, Rachel M. DeVay, Gary Louis Bolton, Christine Bee, Kathy Delaria
Publikováno v:
Bioconjugate Chemistry. 28:1102-1114
Antibody drug conjugates (ADCs) provide an efficacious and relatively safe means by which chemotherapeutic agents can be specifically targeted to cancer cells. In addition to the selection of antibody targets, ADCs offer a modular design that allows
Autor:
Qing Zong, Bernard S. Buetow, Marco Costa, Charles Holz, David L. Shelton, Shu-Hui Liu, Thomas-Toan Tran, Allison Given Chunyk, Pavel Strop, Eileen R. Blasi, Jyothirmayee Kudaravalli, Kathy Delaria, Kevin Lindquist, Wei-Hsien Ho, Angela Stauffer, Jing-Tyan Ma, Magdalena Dorywalska, Arvind Rajpal
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-19 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-19 (2019)
Antibody-drug conjugates (ADCs) are promising therapies for haematological cancers. Historically, their therapeutic benefit is due to ADC targeting of lineage-restricted antigens. The C-X-C motif chemokine receptor 4 (CXCR4) is attractive for targete
Autor:
Cris Kamperschroer, Laura Aschenbrenner, Kevin Lindquist, David L. Shelton, Pascua Edward Derrick, Wei Chen, Pavel Strop, Tracy C. Kuo, Chen Amy Shaw-Ru, Yik Andy Yeung, Jeffrey L. Wolf, Barbra Sasu, Michael Mirsky, Thomas Van Blarcom, Ingrid D. Pardo, Santiago E. Farias, Bing Kuang, Tao Geng, Javier Chaparro-Riggers, Siler Panowski, Bora Han, Marjorie Bateman, Allison Given Chunyk, Russell Dushin, Sherman M. Chin, Kathy Delaria, Yi Zhang, Arvind Rajpal, Thomas G. Martin, Bernard S. Buetow
Publikováno v:
Molecular cancer therapeutics. 18(11)
The restricted expression pattern of B-cell maturation antigen (BCMA) makes it an ideal tumor-associated antigen (TAA) for the treatment of myeloma. BCMA has been targeted by both CD3 bispecific antibody and antibody–drug conjugate (ADC) modalities
Autor:
Kathryn E. Gropp, Lonnie E Grantham, Alison M. Bendele, Brian C Omura, David L. Shelton, Mark Zorbas, Susan Hurst, Thomas Cummings, Cedo M. Bagi, Timothy P. LaBranche
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveTo investigate whether the effects of nerve growth factor (NGF) inhibition with tanezumab on rats with medial meniscal tear (MMT) effectively model rapidly progressive osteoarthritis (RPOA) observed in clinical trials.MethodsMale Lewis rats